Institutional spread of clonally related Serratia marcescens isolates with a novel AmpC cephalosporinase (S4): a 4-year experience in Taiwan

Diagnostic Microbiology and Infectious Disease

Volumn 61, Issue 4, 2008, Pages 460-467

  Yu, Wen Liang ^a,b   Ko, Wen Chien ^c   Cheng, Kuo Chen ^a   Chen, Hui En ^a   Lee, Ching Chien ^a   Chuang, Yin Ching ^a  

^a CHI MEI MEDICAL CENTER   (Taiwan)

^b TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^c NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

Author keywords

AmpC; Epidemiology; Serratia marcescens; SRT family

Indexed keywords

BETA LACTAMASE AMPC; CEFEPIME; CEFOTAXIME; CEFTAZIDIME; CEPHALOSPORINASE; CLAVULANIC ACID; EXTENDED SPECTRUM BETA LACTAMASE;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL GENE; BACTERIAL STRAIN; BACTERIUM ISOLATE; CONTROLLED STUDY; DNA SEQUENCE; GENOTYPE; MOLECULAR EPIDEMIOLOGY; NONHUMAN; NUCLEOTIDE SEQUENCE; PHENOTYPE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PULSED FIELD GEL ELECTROPHORESIS; S4 GENE; SERRATIA MARCESCENS; SRT 1 GENE; SRT 2 GENE; SST 1 GENE; TAIWAN;

ANTI-BACTERIAL AGENTS; BACTEREMIA; BACTERIAL PROTEINS; BETA-LACTAM RESISTANCE; BETA-LACTAMASES; BETA-LACTAMS; BLOOD; CLUSTER ANALYSIS; CROSS INFECTION; DNA FINGERPRINTING; DNA, BACTERIAL; ELECTROPHORESIS, GEL, PULSED-FIELD; EPIDEMIOLOGY, MOLECULAR; HUMANS; POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS, DNA; SEQUENCE HOMOLOGY, AMINO ACID; SERRATIA INFECTIONS; SERRATIA MARCESCENS; TAIWAN;

EID: 47049122736     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2008.03.010     Document Type: Article

References (33)

1. Baraniak A., Fiett J., Sulikowska A., Hryniewicz W., and Gniadkowski M. Countrywide spread of CTX-M-3 extended-spectrum β-lactamase-producing microorganisms of the family Enterobacteriaceae in Poland. Antimicrob. Agents Chemother. 46 (2002) 151-159
2. Cheng K.C., Chuang Y.C., Wu L.T., Huang G.C., and Yu W.L. Clinical experiences of the infections caused by extended-spectrum β-lactamase-producing Serratia marcescens at a medical center in Taiwan. Jpn. J. Infect. Dis. 59 (2006) 147-152
3. Fry D.E., Fry R.V., and Shlaes D.M. Serratial bacteremia in the surgical patient. Am. Surg. 53 (1987) 438-441
4. Hidri N., Barnaud G., Decre D., Cerceau C., Lalande V., Petit J.C., Labia R., and Arlet G. Resistance to ceftazidime is associated with a S220Y substitution in the omega loop of the AmpC β-lactamase of a Serratia marcescens clinical isolate. J. Antimicrob. Chemother. 55 (2005) 496-499
5. Jacoby G.A. Extended-spectrum β-lactamases and other enzymes providing resistance to oxyimino-β-lactams. Infect. Dis. Clin. North. Am. 11 (1997) 875-887
6. Jang T.N., Fung C.P., Yang T.L., Shen S.H., Huang C.S., and Lee S.H. Use of pulsed-field gel electrophoresis to investigate an outbreak of Serratia marcescens infection in a neonatal intensive care unit. J. Hosp. Infect. 48 (2001) 13-19
7. Kim J., and Lim Y.M. Prevalence of derepressed ampC mutants and extended-spectrum β-lactamase producers among clinical isolates of Citrobacter freundii, Enterobacter spp., and Serratia marcescens in Korea: dissemination of CTX-M-3, TEM-52, and SHV-12. J. Clin. Microbiol. 43 (2005) 2452-2455
8. Kim J., Kwon Y., Pai H., Kim J.W., and Cho D.T. Survey of Klebsiella pneumoniae strains producing extended-spectrum β-lactamases: prevalence of SHV-12 and SHV-2a in Korea. J. Clin. Microbiol. 36 (1998) 1446-1449
9. Liu P.Y., Lau Y.J., Hu B.S., Shir J.M., Cheung M.H., Shi Z.Y., and Tsai W.S. Use of PCR to study epidemiology of Serratia marcescens isolates in nosocomial infection. J. Clin. Microbiol. 32 (1994) 1935-1938
10. Luzzaro F., Perilli M., Migliavacca R., Lombardi G., Micheletti P., Agodi A., Stefani S., Amicosante G., and Pagani L. Repeated epidemics caused by extended-spectrum β-lactamase-producing Serratia marcescens strains. Eur. J. Clin. Microbiol. Infect. Dis. 17 (1998) 629-636
11. Mabilat C., and Goussard S. PCR detection and identification of genes for extended-spectrum β-lactamases. In: Persing D., Smith T., Tenover F., and White T. (Eds). Diagnostic molecular microbiology: principles and applications (1995), American Society for Microbiology, Washington, DC 553-557
12. Mammeri H., Poirel L., Bemer P., Drugeon H., and Nordmann P. Resistance to cefepime and cefpirome due to a 4-amino-acid deletion in the chromosome-encoded AmpC β-lactamase of a Serratia marcescens clinical isolate. Antimicrob. Agents. Chemother. 48 (2004) 716-720
13. Matsumura N., and Mitsuhash S. A β-lactamase from Serratia marcescens hydrolyzing the 2-carboxypenam T-5575. Antimicrob. Agents. Chemother. 39 (1995) 2132-2134
14. Matsumura N., Minami S., and Mitsuhash S. Sequences of homologous β-lactamases from clinical isolates of Serratia marcescens with different substrate specificities. Antimicrob. Agents. Chemother. 42 (1998) 176-179
15. Matthew M., Harris A.M., Marshall M.J., and Ross G.W. The use of analytical isoelectric focusing for detection and identification of β-lactamases. J. Gen. Microbiol. 88 (1975) 169-178
16. National Committee for Clinical Laboratory Standards. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically. Approved Standard M7-A6. Wayne, PA: National Committee for Clinical Laboratory Standards (2003)
17. National Committee for Clinical Laboratory Standards. Performance Standards for Antimicrobial Susceptibility Testing. 15th Informational Supplement. M100-S15. MIC Testing. Wayne, PA: National Committee for Clinical Laboratory Standards (2005)
18. Naumiuk L., Baraniak A., Gniadkowski M., Krawczyk B., Rybak B., Sadowy E., Samet A., and Kur J. Molecular epidemiology of Serratia marcescens in two hospitals in Gdansk, Poland, over a 5-year period. J. Clin. Microbiol. 42 (2004) 3108-3116
19. Pan A., Dolcetti L., Barosi C., Catenazzi P., Ceruti T., Ferrari L., Magri S., Roldan E.Q., Soavi L., and Carnevale G. An outbreak of Serratia marcescens bloodstream infections associated with misuse of drug vials in a surgical ward. Infect. Control. Hosp. Epidemiol. 27 (2006) 79-82
20. Peltroche-Llacsahuanga H., Lutticken R., and Haase G. Temporally overlapping nosocomial outbreaks of Serratia marcescens infections: an unexpected result revealed by pulse-field gel electrophoresis. Infect. Control Hosp. Epidemiol. 20 (1999) 387-388
21. Pfaller M.A., Wendt C., Hollis R.J., Wenzel R.P., Fritschel S.J., Neubauer J.J., and Herwaldt L.A. Comparative evaluation of an automated ribotyping system versus pulsed-field gel electrophoresis for epidemiological typing of clinical isolates of Escherichia coli and Pseudomonas aeruginosa from patients with recurrent gram-negative bacteremia. Diag. Microbiol. Infect. Dis. 25 (1996) 1-8
22. Raimondi A., Sisto F., and Nikaido H. Mutation in Serratia marcescens AmpC β-lactamase producing high-level resistance to ceftazidime and cefpirome. Antimicrob. Agents Chemother. 45 (2001) 2331-2339
23. Sanders Jr. W.E., and Sanders C.C. Inducible β-lactamases: clinical and epidemiologic implications for use of newer cephalosporins. Rev. Infect. Dis. 10 (1988) 830-838
24. Schaberg D.R., Alford R.H., Anderson R., Farmer III J.J., Melly M.A., and Schaffner W. An outbreak of nosocomial infection due to multiply resistant Serratia marcescens: evidence of interhospital spread. J. Infect. Dis. 134 (1976) 181-188
25. Silbert S., Boyken L., Hollis R.J., and Pfaller M.A. Improving typeability of multiple bacterial species using pulsed-field gel electrophoresis and thiourea. Diagn. Microbiol. Infect. Dis. 47 (2003) 619-621
26. Su L.H., Ou J.T., Leu H.S., Chiang P.C., Chiu Y.P., Chia J.H., Kuo A.J., Chiu C.H., Chu C., Wu T.L., Sun C.F., Riley T.V., Chang B.J., and Infection Control Group. Extended epidemic of nosocomial urinary tract infections caused by Serratia marcescens. J. Clin. Microbiol. 41 (2003) 4726-4732
27. Tenover F.C., Arbeit R.D., and Goering R.V. How to select and interpret molecular strain typing methods for epidemiological studies of bacterial infections: a review for healthcare epidemiologists. Infect. Control Hosp. Epidemiol. 18 (1997) 426-439
28. Villari P., Crispino M., Salvadori A., and Scarcella A. Molecular epidemiology of an outbreak of Serratia marcescens in a neonatal intensive care unit. Infect. Control Hosp. Epidemiol. 22 (2001) 630-634
29. Wong W.W., Wang L.S., Cheng D.L., Lin S.J., Chin T.D., Hinthorn D.R., O'Connor M.C., and Huang W.K. Serratia marcescens bacteremia. J. Formos. Med. Assoc. 90 (1991) 88-93
30. Wu L.T., Tsou M.F., Wu H.J., Chen H.E., Chuang Y.C., and Yu W.L. Survey of CTX-M-3 extended-spectrum β-lactamase (ESBL) among cefotaxime-resistant Serratia marcescens at a medical center in middle Taiwan. Diagn. Microbiol. Infect. Dis. 49 (2004) 125-129
31. Yu V.L. Serratia marcescens-historical perspective and clinical review. N. Engl. J. Med. 300 (1979) 887-893
32. Yu W.L., Lin C.W., and Wang D.Y. Serratia marcescens bacteremia: clinical features and antimicrobial susceptibilities of the isolates. J. Microbiol. Immunol. Infect. 31 (1998) 171-179
33. Yu W.L., Wu L.T., Pfaller M.A., Winokur P.L., and Jones R.N. Confirmation of extended-spectrum β-lactamase-producing Serratia marcescens: preliminary report from Taiwan. Diagn. Microbiol. Infect. Dis. 45 (2003) 221-224